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"Tebafen" IS a drug which consists of four parts of Isoniazid and one part of
nicotinaldehyde thiosemicarbazone (NAT) which is a Tibione (TBl) analogue synthesized
by Hagenbach and Gysin. NAT has been studied by various investigators since it was
reported by Levaditi," Grunberg" and others that this substance was more effective
than TBI in vivo.
More than one drug is commonly used in combination for treatment of pulmonary
tuberculosis, but the combined therapy of TBI with other drugs is not widely performed
in Japan. According to the writers' experiences with TBl, it is considerably antituber-
culous, but in comparison with streptomycin, p-aminosalicylic acid or isonicotinic acid
hydrazide (lNH) , TBl has disadvantages that it causes loss of appetite more frequently
and is less effective on weight gain.
The combined therapies with the above described drugs, however, are not always
satisfactory in the treatment of pulmonary tuberculosis. In the writers' opinion, many
kinds of drugs which do not produce cross-resistance of tubercle bacilli may be necessary
to treat every case of pulmonary tuberculosis by chemotherapy alone. Consequently, the
present writers intend to utilize TBl as much as possible and expect TBI analogues to be
reformed.
Under this situation, Tebafen was offered to the writers, and preliminary experi-
ments and clinical investigations were performed as follows:
Antituberculous activity in vitro:
1. Bacteriostatic activity of NAT:
The minimum inhibiting concentration of NAT for tubercle bacilli (H37 Rv) in
Kirchner's medium containing 10 per cent serum is almost equal to that of TBl, as may
be seen in table 1. This result is about coincidental with the report by Levad.iti '? that
the minimum inhibitory concentration in Dubas medium was 601' per ml.
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2. Combined effect with INH:
The combined effects of NAT or TBI with INH are illustrated in table 2. INH is
more effective when it is used with either NAT or TBI than when it is used alone. It
appears that the combined use of NAT with INH is more effective than that of TBI
with INH.
Table 2: In Vitro Effects of Combined Use
of INH with NAT or TBI









3. Bacteriostatic activity in the blood:
The experiment was made by inoculating tubercle bacilli (H37 Rv) in Kirchner's
media containing 90 per cent serum which was obtained from human who had been
administered a certain drug, and the length of time that the bacteriostatic activity in the
blood is maintained after administration of the drug was observed (Shioda's Method"),
As may be seen in table 3, the bacteriostatic activity was observed from 3 hours to
7 hours after administration when NAT alone was used.
Table 3: Transitions of Bacteriostatic Activity of Serum
in Kirchner's Medium after Administration of Drug
Case 1240 mg. of INH 160 mg. of NAT 1240 mg. of INH 1240 mg. of INH
number +60 mg. of NAT +60 mg. of TBI
1 up to 7 hrs, 3 to 5 hrs, up to 9 hrs. up to 9 hrs.
2 up to 7 hrs, 3 to 5 hrs. up to 9 hrs, up to 7 hrs.
3 up to 5 hrs. 3 to 5 hrs. up to 4 hrs, up to 7 hrs.
4 up to 7 hrs. 3 to 5 hrs, up to 7 hrs. up to 7 hrs.
5 up to 7 hrs. 3 to 5 hrs, up to 9 hrs, up to 7 hrs,
--
-
The combined use of NAT with INH, namely the use of Tabafen, resulted in a
longer antituberclous effect than use of INH alone.
TBI showed similar but less effect.
4. Therapeutic effect for pulmonary tuberculosis:
From the results of the above mentioned basal experiments, the combined use of
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NAT and INH, namely the use of Tebafen, was considered significant, and clinical
investigations in tuberculous patients were carried out.
Each tablet of Tabafen contains 40 mg. of INH and 10 mg. of NAT. In this labora-
tory. 2 tablets of Tabafen were administered 3 times daily, that is, 240 mg. of INH and
60 mg. of NAT were given daily in combination.
The result of the use of INH alone for a period of 5 months reported by the present
writers'? was employed as control in the present study.
The classification of the clinical findings was based upon the standard of The Com-
mittee of the Therapy of Tuberculosis of the Welfare Ministry. Complete detailed
analysis is not within the scope of the present report. A summary of the results, how-
ever, indicates that:
The effects of therapy on high fever were obscure because of lack of patients who
had high fever at the onset of therapy.
No marked variation between the effects of Tebafen and those of INH on slight
fever was noted. (table 4)
Table 4: Effects of Therapy on Slight Fever
I months subsided I un~han!ed lelevated
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Tebafen 3 27.2 8 72.8 o
------13
INH 34 30.9 76 69.1 2
The effect of drugs on appetite were indistinct, as the appetites were essentially
unaffected in the majority of the patients. (table 5)
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INH alone was more effective for weight gain than Tabafen. (table 6)
Table 6: Effects of Therapy on Body Weight
,--'--- --"•.._----- -------- ---_._-----_.-._--~--_...._- ---
months
markedly gained unchanged I de- Iessentiallygained creased normal






0 8 100.0 1 12
1 ;------1 I --I
__INH -J 4
-I----'=-I




Tebafen 0 2 25.0 6 75.0 1 12




Tebafen 0 2 28.9 5 71.1 1 12
3 ----- - ---
INH 21 lOA
I
55 27.1 127 62.5 7 21
I
Tebafen was more effective than INH in retarding the erythrocytes sedimentation
rates. (table 7)
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2 36 15.1 173 72.7 40 7
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Tebafen 2 , 20.0 4 40.0 4 40.0 1
I
2 ----- ~--- -- ----- -_ ..• ---~~I 33 I 15.0 46 I 2=.0 140 64.0 39 I 7-----Tebafen 4 L:4.:___3__ . 33.3 2 22.3 2
3 - --
I. 11.7 I 35 1 21.5INH
I
19 109 66.8 33
I
6
It appears that INH was slightly more effective than Tebafen on coughs. (table 8)
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Tebafen was markedly more effective than INH on the presence of acid-fast bacilli
in sputum. (table 9)
Table 9: Effects of Therapy on Presence of Tubercle Bacilli iII Sputum
months
became
reduced I unchanged in- essentially
negative I creased negative
of drug -~-- _ .. _-----
treatments No. of I % No. of q,{; I No. of % No. of No. of
.patiants p~ients pct!ie~!s pat~nts patients
Tebafen
I





INH 27 11.9 58 25.6 142 62.5 5 208
Tebafen 5 45.~) 0 6 54.5 1 9
2
INH 40 19.4 57 27.6 109 53.0 5 leo
Tebafen 5 62.5 1 12.5 2 25.0 1 9
3 ~-----
INH 41 25.8 50 31.4 68 42.8 9 81
-- -----.--
Tebafen was more effective than INH to reduce the amount of sputum. (table 10)
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---- ---------1 -----;, ...-----. ·· __·-~---·----I--·----_··__··-
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No remarkable variation between the effects of Tebafen and INH alone on roent-
genographic appearances of the chest was noted. (table 11)
Table 11: Effects of Therapy on Roentgenographic Appearance
Three Months after Start of Treatment
total improved worsened 'roentgenogram
drug No. of No. of No, of was not takeno' 0/ iat this timecases ,0 ~Ocases cases
Tebafen 21 12 57.1 8 38.1 1 4.8 0
-----.------ ..--I
I
INH 128 62 60.7 34 33.3 6 26
5. Side Effect:
No subjective symptoms considered to be caused by drug reactions were noted.
No marked changes were noted in bromsulphalein test for liver function (table 12),
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qualitative test of urobilinogen in the urine (table 13) and blood counts (table 14).
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1 1 6
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1 1 4
2 1 1 2 4
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neutrophils 2 1 I 5
I
differential eosinophils 2 4
I
2
counts monocytes 2 4 I 2
lymphocytes 5 I 1 2
I
Conclusion:
Although no statement relating to the development of drug-resistant strains of
tubercle bacilli can be made at this time, it appears that Tebafen is somewhat more
effective than INH in the basal and clinical investigations described above.
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